Yu Hongwei, Qu Guofan, Wang Yuxue, Mai Wei, Bao Jun Jie, Song Chunyu, Yao Meng
Department of Orthopaedics, The Tumor Hospital Affiliated to Harbin Medical University, No.150, Haping Road, Xiangfang District, Harbin, 150040, Heilongjiang, China.
Department of Orthopaedics, The Second Affiliated Hospital of Harbin Medical University, No. 246, Xuefu Road, Nangang District, Harbin, 150001, Heilongjiang, China.
J Orthop Surg Res. 2019 Apr 11;14(1):103. doi: 10.1186/s13018-019-1137-6.
Osteosarcoma was locally aggressive and frequently metastasizes to the lung. However, the etiology of osteosarcoma was unknown. Thus, exploring the mechanisms behind the occurrence of osteosarcoma was important for its prediction and prevention. To investigate the usefulness of mammalian Eps15 homology domain 1 (EHD1) as a prognostic marker for osteosarcoma, the expression of EHD1 in 57 osteosarcoma patients was measured using immunohistochemistry techniques and correlated with the clinicopathological features of patients.
Correlations of EHD1 expression levels with clinicopathological features of patients were assessed using the Pearson χ test for categorical variables and the Student t test for continuous variables. Cumulative disease-free survival (DFS) curves and overall survival (OS) curves were plotted using the Kaplan-Meier method, and the relationship between each of the variables and survival was assessed by log-rank tests using univariate analysis. Subsequently, the parameters were tested using the multivariate Cox proportional hazards model, which was used to identify independent variables for predicting survival. EHD1 expression [P = 0.020; HR, 5.582; 95% confidence intervals (CI), 1.314-23.72] was an independent prognostic indicator of DFS in osteosarcoma patients; tumor size and EHD1 expression of osteosarcomas were independent prognostic indicators of OS in osteosarcoma patients.
EHD1 protein expression was a positive expression in examined tumor tissues. The median OS time of patients with high expression of EHD1 was 46.8 months (95% CI, 29.8-63.8 months), and the median OS time of patients with low expression of EHD1 was 58.8 months (95% CI, 31.6-86.0 months). The prognosis for patients with low expression of EHD1 in osteosarcomas was significantly better than that for patients with high expression of EHD1 (log-rank test, P = 0.019).
The expression of EHD1 was negatively correlated with DFS and OS of osteosarcoma patients; therefore, the expression of EHD1 is a prognostic marker for prediction and prevention of osteosarcomas.
骨肉瘤具有局部侵袭性,且常转移至肺部。然而,骨肉瘤的病因尚不清楚。因此,探究骨肉瘤发生背后的机制对其预测和预防具有重要意义。为了研究哺乳动物Eps15同源结构域1(EHD1)作为骨肉瘤预后标志物的实用性,采用免疫组织化学技术检测了57例骨肉瘤患者中EHD1的表达,并将其与患者的临床病理特征相关联。
使用Pearson χ检验评估分类变量中EHD1表达水平与患者临床病理特征的相关性,使用Student t检验评估连续变量的相关性。采用Kaplan-Meier法绘制累积无病生存(DFS)曲线和总生存(OS)曲线,并使用单因素分析的对数秩检验评估每个变量与生存之间的关系。随后,使用多变量Cox比例风险模型对参数进行检验,该模型用于识别预测生存的独立变量。EHD1表达[P = 0.020;HR,5.582;95%置信区间(CI),1.314 - 23.72]是骨肉瘤患者DFS的独立预后指标;骨肉瘤的肿瘤大小和EHD1表达是骨肉瘤患者OS的独立预后指标。
EHD1蛋白表达在检测的肿瘤组织中呈阳性表达。EHD1高表达患者的中位OS时间为46.8个月(95%CI,29.8 - 63.8个月),EHD1低表达患者的中位OS时间为58.8个月(95%CI,31.6 - 86.0个月)。骨肉瘤中EHD1低表达患者的预后明显优于EHD1高表达患者(对数秩检验,P = 0.019)。
EHD1的表达与骨肉瘤患者的DFS和OS呈负相关;因此,EHD1的表达是预测和预防骨肉瘤的预后标志物。